Document:

EX-10.1

 Exhibit 10.1 

THRESHOLD PHARMACEUTICALS, INC. 

ADVISORY BOARD AGREEMENT 

THIS AGREEMENT is made and entered into as of the 17 January 2014 (the
“Effective Date”), by and between Threshold Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business at 170 Harbor Way, Suite 300, South San Francisco, CA 94080 (the “Company”), and David R. Parkinson,
M.D., an individual residing at 820 Anderson Lane Sebastopol, CA 95472 (the “Advisor”). 
 1. Engagement of
Services. The Company hereby appoints the Advisor as a member of its Advisory Board. The Advisor agrees to serve as a member of the Company’s Advisory Board; perform the duties of a member of the Advisory Board; meet with other Advisory
Board members as the Company requests; review goals of the Company and develop strategies for achieving them; provide advice, support, leads, contacts, and introductions in the Company’s scientific medical and business activities; and consult
with the Company regarding scientific, medical, and business development matters, as the Company may request from time to time (collectively, the “Services”). The Advisor will participate in Advisory Board meetings telephonically, or in
person if the Company so requires, and otherwise be reasonably available by telephone. The Advisor will perform Services faithfully, diligently, and to the best of the Advisor’s skill and ability. 

2. Compensation. 
 In
consideration of the Advisor’s availability to provide Services, the Company shall pay to the Advisor an hourly fee of $400, not to exceed $10,000 per year, provided that the Company has agreed in advance to the specific projects and scope of
consultation that the Advisor will provide. 
 The Company will also reimburse the Advisor for reasonable travel and other incidental
expenses incurred by Advisor in performing the Services, provided the Company has agreed in advance to reimburse such costs, and the Advisor has provided the Company with such receipts or other relevant documentation as the Company may require for
such reimbursement. 
 3. Independent Contractor. The Advisor is an independent contractor and not an employee of the Company. The
Advisor has no authority to obligate the Company by contract or otherwise. The Advisor is not eligible for any employee benefits. The Company will not make tax deductions from any amounts payable to Advisor; taxes on such payments shall be the
sole responsibility of Advisor. 
 4. Nonsolicitation and Noncompetition. 

(a) During the term of this Agreement and for one (1) year after its termination, the Advisor will not personally or through others
(i) recruit, solicit, or attempt to induce any employee or contractor of the Company to terminate his or her employment or contractual relationship with the Company, or (ii) solicit in direct competition with the Company the business of
any client or customer of the Company. 

 (b) During the term of this Agreement and for six (6) months after its termination,
Advisor will not, without the prior consent of the Company, engage in any business activity which directly competes with any business then being conducted or planned by the Company of which the Advisor has become aware in the course of providing
Services; the foregoing shall not have the effect of preventing Advisor from engaging in any academic research, teaching or related activity. 

(c) If any restriction set forth in Sections 4(a) and 4(b) above is found by any court of competent jurisdiction to be unenforceable
because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities, and geographic area as to which
it is enforceable. 
 5. Company’s Proprietary Rights and Nondisclosure. In providing Services, the Advisor will be exposed to,
have access to, and be engaged in the development of information (including all tangible and intangible manifestations) relating to inventions, patents, copyrights, trademarks, trade secrets, technology, strategic sales/marketing plans, and business
of the Company, and accordingly agrees as follows. 
 (a) The term “Proprietary Information” shall mean all inventions,
works of authorship, trade secrets, business plans, confidential knowledge, data, or any other proprietary information of the Company. By way of illustration but not limitation, “Proprietary Information” includes, without limitation,
(a) inventions, ideas, samples, designs, applications, drawings, methods or processes, formulas, trade secrets, data, source and object codes, know-how, improvements, discoveries, developments, designs, and techniques (hereinafter collectively
referred to as “Inventions”); and (b) information regarding plans for research, development, new products and service offerings, marketing and selling, forecasts, business plans, budgets and unpublished financial statements, licenses,
sales, pricing, profits and costs, distribution arrangements, suppliers and customers, marketing, customer and partner strategies, business development plans, customer and partner lists; and information regarding the skills and compensation of
employees of the Company and the Company’s internal organization. 
 (b) The Advisor agrees promptly to disclose in writing and
hereby assigns to the Company the Advisor’s entire right, title and interest in and to any and all inventions and proprietary information (and all proprietary rights with respect thereto) or any other copyrightable or patentable work, made,
conceived, or reduced to practice by Advisor, either alone or jointly with others, in the course of performing Services, without any obligation of the Company to pay royalty or any other consideration. The Advisor agrees that all such inventions and
proprietary information are the sole property of the Company and will, at the Company’s request, promptly execute a written assignment to the Company of title to any such inventions and proprietary information relating to it and will preserve
any such information as part of the proprietary Information of the Company. The Advisor will keep in confidence and trust all Proprietary Information and shall not reproduce, use, or disclose any Proprietary Information or anything related to such
information without the prior written consent of the Company, except as 

  
 2 

 
required in performing Services. All Proprietary Information, whether presently existing or developed in the future, shall be the sole property of the Company and its assigns. In addition, the
Company and its assigns shall be the sole owner of all intellectual property and other rights in connection with such Proprietary Information. 

(c) The provisions of this Agreement are subject to the understanding that the Advisor is affiliated with, employed by, and/or
consulting with other institution(s) or entity(ies) and must fulfill certain obligations to the Institutions pursuant to the Institutions’ guidelines or policies. If the Advisor is required to disclose Proprietary Information to the Institution
pursuant to applicable guidelines or policies, and such information falls within the Company’s direct focus or interest, then the Advisor shall promptly notify the Company in writing. 

(d) The Advisor will submit to the Company any proposed publication which contains any discussion relating to the Company, the Services,
or Proprietary Information. Advisor agrees not to publish or otherwise disclose any such proposed publication without the prior written consent of the Company, which consent shall not be unreasonably withheld. Any such consent shall be given within
thirty (30) days of receipt of the proposed publication. The Advisor is free to publish any information that does not relate to the Company or the Services and that does not disclose Proprietary Information. 

(e) In the event the Company is unable, after reasonable effort, to secure Advisor’s signature on any document needed to apply for
or prosecute any patent, copyright, or other right or protection relating to an invention subject to assignment to the Company, the Advisor hereby designates and appoints the Company and its duly authorized officers and agents as Advisor’s
agent and attorney-in-fact, to act for and on the Advisor’s behalf to execute, verify and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyrights, and other rights
and protections thereon with the same legal force and effect as if executed by the Advisor. Such appointment shall be irrevocable and coupled with an interest. 

6. Nondisclosure of Third-Party Information. The Advisor understands that the Company has received and will receive from third parties
information that is confidential or proprietary and subject to restrictions on the Company’s use and disclosure (“Third-Party Information”). The Advisor will hold Third-Party Information in the strictest confidence and will not
disclose or use Third-Party Information, except as permitted by agreement between the Company and the relevant third party, unless expressly authorized in writing to act otherwise by an officer of the Company. 

7. Obligation To Keep Company Informed. The Advisor shall promptly disclose to the Company, or any persons designated by it, any and
all proprietary information, whether or not patentable, of which the Advisor becomes aware that relates to Proprietary Information of the Company; however, Advisor shall not be obligated to disclose information received by Advisor from others under
a contractual obligation of confidentiality. 
 8. Prior Inventions. Inventions that the Advisor made prior to the Effective Date are
excluded from the scope of this Agreement. For the avoidance of doubt, the advisor should be prepared to demonstrate, if asked, that such inventions have been documented prior to the Advisor signing this agreement. 

  
 3 

 9. No Conflicting Obligation. The Advisor represents that the Advisor’s performance
of the Services does not and will not breach or conflict with any agreement to which the Advisor is or later becomes a party. The Advisor has not entered into, and agrees not to enter into during the term of this Agreement any agreement, written or
oral, in conflict with this Agreement. 
 10. No Improper Use of Materials. The Advisor agrees not to bring to the Company or to use
in the performance of Services any materials or documents obtained from a present or former employer of the Advisor, the Advisor’s employees, or any other person with whom the Advisor has entered into a confidentiality agreement, unless such
materials or documents are generally available to the public or the Advisor has authorization for the possession and unrestricted use of such materials. In providing the Services, the Advisor agrees not to breach any obligation of confidentiality
that the Advisor has undertaken with the Company or with a third party. 
 11. Term and Termination. Unless previously terminated or
extended, this Agreement will terminate one (1) year from the Effective Date. The Company or Advisor may also terminate this Agreement upon thirty (30) days written notice to the other. The Company may terminate this Agreement immediately
upon written notice by the Company to the Advisor in the event of Advisor’s material breach of this agreement or any misconduct by Advisor that could have an adverse effect on the business of the Company. Any determination of such breach or
misconduct as used herein shall be made in the Company’s sole discretion. The obligations set forth in Sections 4, 5, and 6 survive any termination of this Agreement. Upon termination of this Agreement, the Advisor will promptly deliver to the
Company all documents and other materials of any nature pertaining to the Services, together with all documents and other items containing or pertaining to any Proprietary Information. The Advisor shall not retain copies of any such documents or
other materials after termination of this Agreement. 
 12. Legal and Equitable Remedies. Because the Advisor’s services are
personal and unique and because the Advisor may have access to and become acquainted with Proprietary Information, the Company shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance, or other
equitable relief without prejudice to any other rights and remedies that the Company may have for a breach of this Agreement, without bond. 

13. General Terms. The parties’ rights and obligations will bind and inure to the benefit of their respective successors, heirs,
executors and administrators, and permitted assigns. Because the nature of the Services is personal, any attempted assignment of Advisor’s rights or delegation of Advisor’s obligations will be void without the prior written consent of the
Company. This Agreement is governed by the laws of the State of Delaware, excluding conflicts of laws principles. If any provision of this Agreement is found by a proper authority to be unenforceable, then that provision shall be severed, and the
remainder of this Agreement will continue in full force and effect. This Agreement and its Exhibits constitute the parties’ final, exclusive, and complete understanding and agreement with respect to the subject matter hereof, and supersede all
prior and contemporaneous understandings and agreements relating to its subject matter. Any waiver, modification, or amendment of any provision of this Agreement shall be effective only if 

  
 4 

 
in writing and signed by the parties to this Agreement. Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at such other address
as the party shall specify in writing. Such notice shall be deemed given upon personal delivery, or sent by certified or registered mail, postage prepaid, three (3) days after the date of mailing. This Agreement may be executed in one or more
counterparts, each of which will be deemed an original, but all of which together shall constitute one and the same instrument. 
 The
parties hereto have executed this ADVISORY BOARD AGREEMENT as of the Effective Date. 
  

									
	THRESHOLD PHARMACEUTICALS, INC.	 		 	ADVISOR
					
	By: 	 	 /s/ Harold E. Selick, Ph.D.
	 		 	By: 	 	 /s/ David R. Parkinson, M.D.

	Name:	 	Harold E. Selick, Ph.D.	 		 	Name:	 	David R. Parkinson, M.D.
	Title:	 	CHIEF EXECUTIVE OFFICER	 		 	Tax ID:
					
	Date:	 	March19, 2014	 		 	Date:	 	March 20, 2014

  
 5EX-10.2

 Exhibit 10.2 

THRESHOLD PHARMACEUTICALS, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 

ADOPTED BY THE BOARD OF DIRECTORS:
MARCH 20, 2014 
 Each member of the board of directors (the “Board”) of Threshold
Pharmaceuticals, Inc. (the “Company”) who is not an employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”) will be eligible to receive cash and equity
compensation as set forth in this Threshold Pharmaceuticals, Inc. Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this Policy will be paid or granted, as applicable,
automatically and without further action of the Board to each Non-Employee Director who is eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written
notice to the Company. This Policy will become effective on the date of the annual meeting of the Company’s stockholders held in 2014, provided that the Threshold Pharmaceuticals, Inc. 2014 Equity Incentive Plan (the “2014
Plan”) is approved by the Company’s stockholders at such annual meeting, and will remain in effect until it is revised or rescinded by further action of the Board. Capitalized terms not explicitly defined in this Policy but defined
in the 2014 Plan will have the same definitions as in the 2014 Plan. 
 1. CASH COMPENSATION. 

(a) Annual Fees. Each Non-Employee Director will be eligible to receive the following annual fees for service as (i) a member of
the Board and (ii) a member or chairperson of a committee of the Board (“Committee”) set forth below, as applicable, to be paid in the form of annual retainers: 

 

							
	 Board or Committee
	  	 Type of Fee
	  	Amount (Per Year)	 
	 Board
	  	Retainer Fee	  	$	30,000	  
	 Audit Committee
	  	Chair Retainer Fee	  	$	20,000	  
		  	Non-Chair Retainer Fee	  	$	11,000	  
	 Compensation Committee
	  	Chair Retainer Fee	  	$	14,000	  
		  	Non-Chair Retainer Fee	  	$	11,000	  
	 Nominating and
	  	Chair Retainer Fee	  	$	14,000	  
	 Governance Committee
	  	Non-Chair Retainer Fee	  	$	11,000	  

 (b) Expenses. Each Non-Employee Director will be entitled to reimbursement from the Company for all
reasonable out-of-pocket expenses incurred by the Non-Employee Director in connection with his or her attendance at Board and Committee meetings. 

 To the extent that any taxable reimbursements are provided to a Non-Employee Director, they will
be provided in accordance with Section 409A of the Internal Revenue Code of 1986, as amended, and the Treasury Regulations and other guidance thereunder and any state law of similar effect, including, but not limited to, the following
provisions: (i) the amount of any such expenses eligible for reimbursement during the Non-Employee Director’s taxable year may not affect the expenses eligible for reimbursement in any other taxable year; (ii) the reimbursement of an
eligible expense must be made no later than the last day of the Non-Employee Director’s taxable year that immediately follows the taxable year in which the expense was incurred; and (iii) the right to any reimbursement may not be subject
to liquidation or exchange for another benefit. 
 2. EQUITY COMPENSATION. The options described in this Policy
will be granted under the 2014 Plan and will be subject to the terms and conditions of (i) this Policy, (ii) the 2014 Plan and (iii) the forms of option grant notices and option agreements approved by the Board for the grant of
options to Non-Employee Directors. 
 (a) Initial Grants. Each individual who is elected or appointed for the first time to be a
Non-Employee Director automatically will be granted, on the date of such initial election or appointment, a nonstatutory stock option to purchase 35,000 shares of Common Stock (an “Initial Option Grant”). 

(b) Annual Grants. On the date of each annual meeting of the Company’s stockholders, each individual who is then a Non-Employee
Director and will be continuing as a Non-Employee Director following the date of such annual meeting automatically will be granted a nonstatutory stock option to purchase 20,000 shares of Common Stock (an “Annual Option
Grant”), provided that such individual has served as a Non-Employee Director for at least six (6) months prior to the date of such annual meeting. 

(c) Terms of Options. 

(i) Exercise Price. The exercise price of each Initial Option Grant and Annual Option Grant will be equal to 100% of the Fair
Market Value of the Common Stock subject to the option on the date the option is granted. 
 (ii) Vesting. Subject to
Section 3 below, each Initial Option Grant and Annual Option Grant will vest and become exercisable as follows: 
 (A) Each
Initial Option Grant will vest and become exercisable as to 2.7777% of the shares of Common Stock subject to the option on each monthly anniversary of the date of grant, rounded down to the nearest whole share, subject to the Non-Employee
Director’s Continuous Service through such dates. 
 (B) Each Annual Option Grant will vest and become exercisable as to 8.3333%
of the shares of Common Stock subject to the option on each monthly anniversary of the date of grant for the first 11 months following the date of grant, rounded down to the nearest whole share, and as to the remaining shares of Common Stock subject
to the option on the date of the annual meeting of the Company’s stockholders for the year following the year of grant for such option, subject to the Non-Employee Director’s Continuous Service through such dates. 

  
 2 

 3. CERTAIN TRANSACTIONS AND EVENTS. 

(a) Fundamental Transaction. The provisions of this Section 3(a) (and not Section 9(c) of the 2014 Plan) will apply to all
outstanding Initial Option Grants and Annual Option Grants in the event of a Fundamental Transaction. In the event of a Fundamental Transaction while a Participant remains a Non-Employee Director, the shares of Common Stock at the time subject to
each outstanding Initial Option Grant and Annual Option Grant held by such Participant, but not otherwise vested, will automatically vest in full so that each such Initial Option Grant and Annual Option Grant will, immediately prior to the effective
date of the Fundamental Transaction, become exercisable for all the shares of Common Stock subject to such Initial Option Grant and Annual Option Grant as fully vested shares and may be exercised for any or all of those vested shares. Immediately
following the consummation of the Fundamental Transaction, each Initial Option Grant and Annual Option Grant will terminate and cease to be outstanding, except to the extent assumed by the successor corporation (or Affiliate thereof). 

Each Initial Option Grant and Annual Option Grant which is assumed in connection with a Fundamental Transaction will be appropriately
adjusted, immediately after such Fundamental Transaction, to apply to the number and class of securities which would have been issuable to the Participant in consummation of such Fundamental Transaction had the Initial Option Grant or Annual Option
Grant been exercised immediately prior to such Fundamental Transaction. Appropriate adjustments will also be made to the exercise price payable per share under each outstanding Initial Option Grant and Annual Option Grant, provided that the
aggregate exercise price payable for such securities will remain the same. To the extent the actual holders of the Common Stock receive cash consideration for their Common Stock in consummation of the Fundamental Transaction, the successor
corporation may, in connection with the assumption of the outstanding Initial Option Grants and Annual Option Grants, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share
of Common Stock in such Fundamental Transaction. 
 (b) Change in Control. In the event of a Change in Control while a Participant
remains a Non-Employee Director, the shares of Common Stock at the time subject to each outstanding Initial Option Grant and Annual Option Grant held by such Participant, but not otherwise vested, will automatically vest in full so that each such
Initial Option Grant and Annual Option Grant will, immediately prior to the effective date of the Change in Control, become exercisable for all the shares of Common Stock subject to such Initial Option Grant and Annual Option Grant as fully vested
shares and may be exercised for any or all of those vested shares. Each such Initial Option Grant and Annual Option Grant will remain exercisable for such fully vested shares until the expiration or sooner termination of the option term in
connection with a Change in Control. 

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]